Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Pre-Exposure Prophylaxis | 4 | 2019 | 1138 | 1.22 | Why? |
Anti-HIV Agents | 6 | 2019 | 2209 | 1.12 | Why? |
Meningitis, Pneumococcal | 1 | 2021 | 35 | 0.88 | Why? |
Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 66 | 0.85 | Why? |
Darunavir | 3 | 2020 | 477 | 0.84 | Why? |
Sexually Transmitted Diseases | 2 | 2019 | 694 | 0.82 | Why? |
HIV Infections | 11 | 2021 | 11620 | 0.80 | Why? |
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2018 | 3 | 0.78 | Why? |
Tuberculosis, Meningeal | 1 | 2021 | 100 | 0.78 | Why? |
Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 26 | 0.76 | Why? |
Rilpivirine | 1 | 2018 | 65 | 0.73 | Why? |
HIV Seropositivity | 2 | 2018 | 320 | 0.73 | Why? |
Alanine | 4 | 2021 | 5687 | 0.58 | Why? |
Adenosine Monophosphate | 3 | 2021 | 5652 | 0.56 | Why? |
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.55 | Why? |
Insulin Resistance | 1 | 2018 | 669 | 0.49 | Why? |
Homosexuality, Male | 3 | 2019 | 1158 | 0.49 | Why? |
Enterocolitis | 1 | 2013 | 62 | 0.47 | Why? |
Antimicrobial Stewardship | 1 | 2020 | 931 | 0.47 | Why? |
Sexual Behavior | 2 | 2019 | 1322 | 0.46 | Why? |
Germany | 18 | 2021 | 9196 | 0.45 | Why? |
Immunocompetence | 1 | 2013 | 280 | 0.44 | Why? |
Emtricitabine | 2 | 2019 | 202 | 0.35 | Why? |
Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.35 | Why? |
Tenofovir | 3 | 2020 | 449 | 0.34 | Why? |
Bacterial Infections | 1 | 2020 | 2229 | 0.32 | Why? |
Home Care Services | 1 | 2018 | 1351 | 0.31 | Why? |
Cytomegalovirus Infections | 1 | 2013 | 667 | 0.31 | Why? |
Adenine | 2 | 2019 | 463 | 0.31 | Why? |
Antiretroviral Therapy, Highly Active | 3 | 2020 | 952 | 0.29 | Why? |
Point-of-Care Testing | 1 | 2018 | 2782 | 0.28 | Why? |
Blood Glucose | 1 | 2018 | 3642 | 0.27 | Why? |
Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.26 | Why? |
Communicable Diseases | 1 | 2018 | 2148 | 0.24 | Why? |
HIV | 2 | 2020 | 1116 | 0.24 | Why? |
Ritonavir | 1 | 2017 | 4212 | 0.24 | Why? |
Spirochaetales Infections | 1 | 2021 | 10 | 0.23 | Why? |
Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.23 | Why? |
Extravascular Lung Water | 1 | 2021 | 32 | 0.23 | Why? |
Sulbactam | 1 | 2020 | 37 | 0.22 | Why? |
Ampicillin | 1 | 2020 | 73 | 0.22 | Why? |
Brain Abscess | 1 | 2021 | 50 | 0.22 | Why? |
Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.21 | Why? |
Antiviral Agents | 4 | 2021 | 41703 | 0.21 | Why? |
Bile Duct Diseases | 1 | 2019 | 12 | 0.20 | Why? |
Linezolid | 1 | 2020 | 160 | 0.20 | Why? |
Glucose Clamp Technique | 1 | 2018 | 39 | 0.19 | Why? |
Bile | 1 | 2019 | 56 | 0.19 | Why? |
Extracorporeal Circulation | 1 | 2020 | 130 | 0.19 | Why? |
Blood Platelets | 2 | 2021 | 1704 | 0.19 | Why? |
Mountaineering | 1 | 2018 | 20 | 0.19 | Why? |
Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
Asymptomatic Infections | 1 | 2018 | 7218 | 0.18 | Why? |
Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.18 | Why? |
Community-Acquired Infections | 2 | 2021 | 2328 | 0.18 | Why? |
Hearing Disorders | 1 | 2019 | 62 | 0.18 | Why? |
Lymphoma, AIDS-Related | 1 | 2017 | 13 | 0.18 | Why? |
Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.18 | Why? |
Cobicistat | 1 | 2019 | 172 | 0.18 | Why? |
Postural Balance | 1 | 2019 | 144 | 0.18 | Why? |
Chemotherapy, Adjuvant | 1 | 2021 | 606 | 0.17 | Why? |
Chlamydia trachomatis | 1 | 2019 | 172 | 0.17 | Why? |
Infectious Disease Medicine | 1 | 2020 | 311 | 0.17 | Why? |
Neoplasms, Second Primary | 1 | 2018 | 100 | 0.17 | Why? |
Enterobacteriaceae Infections | 2 | 2020 | 529 | 0.17 | Why? |
Vancomycin | 1 | 2020 | 328 | 0.17 | Why? |
Streptococcal Infections | 1 | 2020 | 255 | 0.17 | Why? |
Aspergillosis | 1 | 2020 | 264 | 0.16 | Why? |
Escherichia coli Infections | 1 | 2020 | 348 | 0.16 | Why? |
Pulmonary Edema | 1 | 2021 | 430 | 0.16 | Why? |
Adult | 27 | 2021 | 244371 | 0.16 | Why? |
Drug Administration Schedule | 2 | 2020 | 2324 | 0.16 | Why? |
Administration, Intravenous | 1 | 2020 | 1115 | 0.16 | Why? |
Leg | 1 | 2017 | 142 | 0.16 | Why? |
Vascular Calcification | 1 | 2020 | 396 | 0.16 | Why? |
Chlamydia Infections | 1 | 2019 | 248 | 0.15 | Why? |
Carcinoma, Basal Cell | 1 | 2018 | 144 | 0.15 | Why? |
Fluorenes | 1 | 2016 | 101 | 0.15 | Why? |
Male | 32 | 2021 | 367725 | 0.15 | Why? |
Oxazines | 1 | 2017 | 279 | 0.15 | Why? |
CD4 Lymphocyte Count | 2 | 2019 | 1517 | 0.15 | Why? |
Humans | 48 | 2021 | 930598 | 0.15 | Why? |
Klebsiella Infections | 1 | 2020 | 466 | 0.15 | Why? |
Spatial Analysis | 1 | 2021 | 878 | 0.15 | Why? |
Gonorrhea | 1 | 2019 | 315 | 0.14 | Why? |
Middle Aged | 27 | 2021 | 270681 | 0.14 | Why? |
Syphilis | 1 | 2019 | 318 | 0.14 | Why? |
Piperazines | 1 | 2017 | 445 | 0.14 | Why? |
Treatment Outcome | 7 | 2021 | 51732 | 0.14 | Why? |
Lymphoma, Non-Hodgkin | 1 | 2017 | 403 | 0.13 | Why? |
Cholecalciferol | 1 | 2017 | 246 | 0.13 | Why? |
Benzimidazoles | 1 | 2016 | 275 | 0.13 | Why? |
Invasive Pulmonary Aspergillosis | 1 | 2021 | 634 | 0.13 | Why? |
Leukocytes | 1 | 2021 | 1046 | 0.13 | Why? |
Gambling | 1 | 2017 | 183 | 0.13 | Why? |
Chromatography, High Pressure Liquid | 1 | 2017 | 669 | 0.13 | Why? |
Prospective Studies | 7 | 2021 | 43301 | 0.13 | Why? |
Patient Acuity | 1 | 2020 | 1755 | 0.13 | Why? |
Healthy Volunteers | 1 | 2018 | 1444 | 0.12 | Why? |
Body Weight | 1 | 2018 | 1074 | 0.12 | Why? |
Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 800 | 0.12 | Why? |
Sofosbuvir | 1 | 2016 | 518 | 0.11 | Why? |
Pyridones | 1 | 2017 | 738 | 0.11 | Why? |
Female | 27 | 2021 | 380317 | 0.11 | Why? |
Plasma | 2 | 2021 | 1809 | 0.11 | Why? |
Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.11 | Why? |
Staphylococcal Infections | 1 | 2020 | 1099 | 0.11 | Why? |
Lymphocyte Activation | 1 | 2021 | 2742 | 0.11 | Why? |
Pneumonia | 2 | 2021 | 5652 | 0.11 | Why? |
Shock, Septic | 1 | 2021 | 1313 | 0.11 | Why? |
Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.11 | Why? |
Aged | 20 | 2021 | 215776 | 0.10 | Why? |
Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
Antifungal Agents | 1 | 2020 | 1828 | 0.10 | Why? |
Behavior, Addictive | 1 | 2017 | 535 | 0.10 | Why? |
Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.10 | Why? |
Kidney Diseases | 1 | 2020 | 1434 | 0.10 | Why? |
HIV-1 | 3 | 2019 | 3365 | 0.09 | Why? |
Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.09 | Why? |
Ultraviolet Rays | 1 | 2018 | 1272 | 0.09 | Why? |
Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
Odds Ratio | 1 | 2020 | 5861 | 0.09 | Why? |
Vitamins | 1 | 2017 | 1208 | 0.09 | Why? |
Pneumonia, Viral | 6 | 2021 | 243684 | 0.09 | Why? |
Cytomegalovirus | 1 | 2013 | 600 | 0.08 | Why? |
Hepacivirus | 1 | 2016 | 1509 | 0.08 | Why? |
Aged, 80 and over | 10 | 2021 | 88759 | 0.08 | Why? |
Lung Diseases | 1 | 2020 | 2361 | 0.08 | Why? |
Cohort Studies | 5 | 2020 | 36005 | 0.08 | Why? |
Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
Coinfection | 3 | 2020 | 6820 | 0.08 | Why? |
Young Adult | 10 | 2021 | 93724 | 0.08 | Why? |
Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
Coronary Artery Disease | 1 | 2020 | 2570 | 0.08 | Why? |
Severity of Illness Index | 7 | 2021 | 48226 | 0.08 | Why? |
CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
Hepatitis C | 1 | 2016 | 1514 | 0.07 | Why? |
Cardiovascular Diseases | 2 | 2020 | 11497 | 0.07 | Why? |
Tuberculosis | 1 | 2021 | 2895 | 0.07 | Why? |
Skin Neoplasms | 1 | 2018 | 1679 | 0.07 | Why? |
Disease Progression | 2 | 2021 | 13580 | 0.07 | Why? |
Prevalence | 4 | 2021 | 25773 | 0.07 | Why? |
Sepsis | 1 | 2021 | 3517 | 0.06 | Why? |
Models, Statistical | 1 | 2021 | 5312 | 0.06 | Why? |
Pandemics | 10 | 2021 | 389249 | 0.06 | Why? |
Vitamin D Deficiency | 1 | 2017 | 1782 | 0.06 | Why? |
Betacoronavirus | 5 | 2020 | 204454 | 0.06 | Why? |
Psoriasis | 1 | 2017 | 1739 | 0.06 | Why? |
Occupational Diseases | 1 | 2018 | 2787 | 0.06 | Why? |
Adolescent | 7 | 2021 | 86841 | 0.06 | Why? |
Substance-Related Disorders | 1 | 2017 | 2038 | 0.06 | Why? |
Diagnosis, Differential | 2 | 2017 | 7220 | 0.06 | Why? |
Mesylates | 1 | 2021 | 33 | 0.06 | Why? |
Thermodilution | 1 | 2021 | 62 | 0.06 | Why? |
Retrospective Studies | 7 | 2021 | 105322 | 0.06 | Why? |
Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2021 | 72 | 0.05 | Why? |
Galactose | 1 | 2021 | 201 | 0.05 | Why? |
Respiratory Tract Infections | 1 | 2021 | 6817 | 0.05 | Why? |
Granzymes | 1 | 2021 | 197 | 0.05 | Why? |
Urea | 1 | 2021 | 228 | 0.05 | Why? |
Mannans | 1 | 2021 | 218 | 0.05 | Why? |
Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
Age Factors | 4 | 2021 | 21039 | 0.05 | Why? |
Occupational Exposure | 1 | 2018 | 4742 | 0.05 | Why? |
P-Selectin | 1 | 2021 | 224 | 0.05 | Why? |
Capillary Permeability | 1 | 2021 | 277 | 0.05 | Why? |
Hearing Tests | 1 | 2019 | 76 | 0.05 | Why? |
Esters | 1 | 2021 | 300 | 0.05 | Why? |
Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
Enterococcus | 1 | 2019 | 73 | 0.05 | Why? |
Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
HLA-DR Antigens | 1 | 2021 | 563 | 0.05 | Why? |
RNA, Viral | 4 | 2020 | 32276 | 0.04 | Why? |
Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
Anonymous Testing | 1 | 2017 | 2 | 0.04 | Why? |
Sunscreening Agents | 1 | 2018 | 63 | 0.04 | Why? |
Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
Hospitalization | 4 | 2021 | 54280 | 0.04 | Why? |
Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
Heterosexuality | 1 | 2018 | 148 | 0.04 | Why? |
Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
Guanidines | 1 | 2021 | 499 | 0.04 | Why? |
Iatrogenic Disease | 1 | 2019 | 304 | 0.04 | Why? |
Alkaline Phosphatase | 1 | 2017 | 257 | 0.04 | Why? |
Superinfection | 1 | 2021 | 459 | 0.04 | Why? |
Interleukin-17 | 1 | 2021 | 602 | 0.04 | Why? |
Blood Component Transfusion | 1 | 2021 | 740 | 0.04 | Why? |
Hypocalcemia | 1 | 2017 | 120 | 0.04 | Why? |
Drainage | 1 | 2019 | 414 | 0.04 | Why? |
Blood Pressure Determination | 1 | 2019 | 450 | 0.04 | Why? |
Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
Enterobacteriaceae | 1 | 2019 | 395 | 0.04 | Why? |
Viral Load | 3 | 2020 | 15850 | 0.04 | Why? |
Holidays | 1 | 2018 | 311 | 0.04 | Why? |
Immunization, Passive | 2 | 2021 | 10067 | 0.04 | Why? |
Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
Lung | 2 | 2021 | 31049 | 0.03 | Why? |
Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
Surveys and Questionnaires | 2 | 2018 | 43792 | 0.03 | Why? |
Carbon Dioxide | 1 | 2020 | 917 | 0.03 | Why? |
T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.03 | Why? |
Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
Public Health | 1 | 2019 | 16359 | 0.03 | Why? |
History, 21st Century | 1 | 2020 | 1849 | 0.03 | Why? |
Risk Assessment | 3 | 2021 | 25439 | 0.03 | Why? |
Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
Practice Guidelines as Topic | 3 | 2021 | 15421 | 0.03 | Why? |
Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
Calcium | 1 | 2017 | 708 | 0.03 | Why? |
Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
Primary Prevention | 1 | 2018 | 778 | 0.03 | Why? |
Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
Coronary Angiography | 1 | 2020 | 2275 | 0.03 | Why? |
Drug Resistance, Multiple, Bacterial | 1 | 2019 | 1115 | 0.03 | Why? |
Killer Cells, Natural | 1 | 2021 | 2093 | 0.03 | Why? |
Bacteria | 1 | 2021 | 1897 | 0.03 | Why? |
Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.03 | Why? |
Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
Monitoring, Physiologic | 1 | 2021 | 1956 | 0.03 | Why? |
Intensive Care Units | 3 | 2021 | 29594 | 0.03 | Why? |
Cluster Analysis | 1 | 2018 | 3001 | 0.02 | Why? |
Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.02 | Why? |
Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
Viruses | 1 | 2021 | 2238 | 0.02 | Why? |
Double-Blind Method | 1 | 2019 | 5988 | 0.02 | Why? |
Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
Motivation | 1 | 2018 | 1640 | 0.02 | Why? |
Blood Pressure | 1 | 2019 | 2198 | 0.02 | Why? |
Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
Serologic Tests | 1 | 2021 | 4359 | 0.02 | Why? |
Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
Early Detection of Cancer | 1 | 2018 | 1956 | 0.02 | Why? |
Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
Algorithms | 1 | 2021 | 7346 | 0.02 | Why? |
Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
Europe | 1 | 2020 | 12702 | 0.02 | Why? |
Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
Drug Therapy, Combination | 1 | 2016 | 7268 | 0.02 | Why? |
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
Spain | 1 | 2020 | 15545 | 0.01 | Why? |
Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
Models, Theoretical | 1 | 2019 | 6659 | 0.01 | Why? |
Health Behavior | 1 | 2018 | 4449 | 0.01 | Why? |
Mass Screening | 1 | 2019 | 8005 | 0.01 | Why? |
Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
Italy | 1 | 2020 | 38444 | 0.01 | Why? |
Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
Child | 1 | 2021 | 70012 | 0.01 | Why? |
Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |